Bioxytran, Inc. (BIXT)
OTCMKTS · Delayed Price · Currency is USD
0.1621
-0.0117 (4.58%)
Apr 25, 2025, 4:00 PM EDT

Bioxytran Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-2.37-4.47-2.46-4.03-2.48
Upgrade
Depreciation & Amortization
0.010.010--
Upgrade
Other Amortization
0.680.350.310.080.26
Upgrade
Stock-Based Compensation
0.630.180.180.580.25
Upgrade
Other Operating Activities
-0.24-0.04-0.14-0.50.61
Upgrade
Change in Accounts Receivable
----0.05
Upgrade
Change in Accounts Payable
1.232.220.31.90.49
Upgrade
Change in Other Net Operating Assets
-0.99-0.27-0.27
Upgrade
Operating Cash Flow
-0.06-0.78-1.81-1.7-1.1
Upgrade
Sale (Purchase) of Intangibles
-0.03-0.04-0.03-0.04-0.01
Upgrade
Investing Cash Flow
-0.03-0.04-0.03-0.04-0.01
Upgrade
Short-Term Debt Issued
--1.381.170.26
Upgrade
Total Debt Issued
--1.381.170.26
Upgrade
Short-Term Debt Repaid
-----0.23
Upgrade
Total Debt Repaid
-----0.23
Upgrade
Net Debt Issued (Repaid)
--1.381.170.03
Upgrade
Issuance of Common Stock
0.060.550.68--
Upgrade
Other Financing Activities
---0.60.95
Upgrade
Financing Cash Flow
0.060.552.061.770.98
Upgrade
Net Cash Flow
-0.02-0.270.220.03-0.13
Upgrade
Cash Interest Paid
0.160.050.1-0.09
Upgrade
Levered Free Cash Flow
-1.07-2.54-0.86-1.43-0.83
Upgrade
Unlevered Free Cash Flow
-1.26-2.42-0.84-1.31-0.29
Upgrade
Change in Net Working Capital
0.480.18-0.34-0.77-0.26
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.